Impact of obinutuzumab alone and in combination for follicular lymphoma

Maryam Sarraf Yazdy, Bruce D Cheson Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA Abstract: Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarraf Yazdy M, Cheson BD
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Obinutuzumab follicular lymphoma MRD monoclonal antibody Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/259d4bf0f16349c4983cd5e49a0ed804
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:259d4bf0f16349c4983cd5e49a0ed804
record_format	dspace
spelling	oai:doaj.org-article:259d4bf0f16349c4983cd5e49a0ed8042021-12-02T01:46:50ZImpact of obinutuzumab alone and in combination for follicular lymphoma1179-9889https://doaj.org/article/259d4bf0f16349c4983cd5e49a0ed8042017-10-01T00:00:00Zhttps://www.dovepress.com/impact-of-obinutuzumab-alone-and-in-combination-for-follicular-lymphom-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Maryam Sarraf Yazdy, Bruce D Cheson Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA Abstract: Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory setting, but also for initial treatment. Obinutuzumab (G, GA101) is a third-generation, fully humanized type II glycoengineered, anti-CD20 monoclonal antibody that results in increased direct cell death and antibody-dependent, cell-mediated cytotoxicity/phagocytosis compared to rituximab. Obinutuzumab has significant antitumor activity when used alone or in combinations in untreated or relapsed refractory FL patients. Studies have demonstrated its ability to prolong progression-free survival and, in some cases, overall survival, and to eliminate minimal residual disease. Several ongoing trials are investigating combinations with chemotherapy, immunomodulators, targeted drugs, and immunotherapy agents. G is generally well tolerated, with associated adverse effects including infusion-related reactions, neutropenia, thrombocytopenia, and reactivation of hepatitis B virus. Future studies with this antibody should focus on identifying predictive markers and developing chemotherapy-free combinations that will improve the outcome of patients with FL. Keywords: obinutuzumab, follicular lymphoma, MRD, monoclonal antibodySarraf Yazdy MCheson BDDove Medical PressarticleObinutuzumabfollicular lymphomaMRDmonoclonal antibodyDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 7, Pp 73-83 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Obinutuzumab follicular lymphoma MRD monoclonal antibody Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Obinutuzumab follicular lymphoma MRD monoclonal antibody Diseases of the blood and blood-forming organs RC633-647.5 Sarraf Yazdy M Cheson BD Impact of obinutuzumab alone and in combination for follicular lymphoma
description	Maryam Sarraf Yazdy, Bruce D Cheson Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA Abstract: Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory setting, but also for initial treatment. Obinutuzumab (G, GA101) is a third-generation, fully humanized type II glycoengineered, anti-CD20 monoclonal antibody that results in increased direct cell death and antibody-dependent, cell-mediated cytotoxicity/phagocytosis compared to rituximab. Obinutuzumab has significant antitumor activity when used alone or in combinations in untreated or relapsed refractory FL patients. Studies have demonstrated its ability to prolong progression-free survival and, in some cases, overall survival, and to eliminate minimal residual disease. Several ongoing trials are investigating combinations with chemotherapy, immunomodulators, targeted drugs, and immunotherapy agents. G is generally well tolerated, with associated adverse effects including infusion-related reactions, neutropenia, thrombocytopenia, and reactivation of hepatitis B virus. Future studies with this antibody should focus on identifying predictive markers and developing chemotherapy-free combinations that will improve the outcome of patients with FL. Keywords: obinutuzumab, follicular lymphoma, MRD, monoclonal antibody
format	article
author	Sarraf Yazdy M Cheson BD
author_facet	Sarraf Yazdy M Cheson BD
author_sort	Sarraf Yazdy M
title	Impact of obinutuzumab alone and in combination for follicular lymphoma
title_short	Impact of obinutuzumab alone and in combination for follicular lymphoma
title_full	Impact of obinutuzumab alone and in combination for follicular lymphoma
title_fullStr	Impact of obinutuzumab alone and in combination for follicular lymphoma
title_full_unstemmed	Impact of obinutuzumab alone and in combination for follicular lymphoma
title_sort	impact of obinutuzumab alone and in combination for follicular lymphoma
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/259d4bf0f16349c4983cd5e49a0ed804
work_keys_str_mv	AT sarrafyazdym impactofobinutuzumabaloneandincombinationforfollicularlymphoma AT chesonbd impactofobinutuzumabaloneandincombinationforfollicularlymphoma
_version_	1718402884778852352

Impact of obinutuzumab alone and in combination for follicular lymphoma

Ejemplares similares